Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.
Front Immunol
; 13: 1058531, 2022.
Article
in En
| MEDLINE
| ID: mdl-36544755
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Squamous Cell
/
Carcinoma, Non-Small-Cell Lung
/
Adenocarcinoma of Lung
/
Lung Neoplasms
Type of study:
Prognostic_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Front Immunol
Year:
2022
Document type:
Article
Affiliation country:
France
Country of publication:
Switzerland